On January 11, Medicare issued a draft memorandum that it will only pay for Aduhelm under the so-called coverage with evidence development (CED) pathway. On one hand, proponents say Medicare can learn whether the drug works in the context of a CED study. On the other, critics say CED impedes access.
Medicare Proposes Restricting Coverage Of Aduhelm To Alzheimer’s Patients Who Enroll In Clinical Trials
